[go: up one dir, main page]

RU2013119044A - MEANS FOR NORMALIZATION OF SLEEP AND BIOLOGICAL RHYTHMS - Google Patents

MEANS FOR NORMALIZATION OF SLEEP AND BIOLOGICAL RHYTHMS Download PDF

Info

Publication number
RU2013119044A
RU2013119044A RU2013119044/15A RU2013119044A RU2013119044A RU 2013119044 A RU2013119044 A RU 2013119044A RU 2013119044/15 A RU2013119044/15 A RU 2013119044/15A RU 2013119044 A RU2013119044 A RU 2013119044A RU 2013119044 A RU2013119044 A RU 2013119044A
Authority
RU
Russia
Prior art keywords
tool according
gamma
derivative
components
aminobutyric acid
Prior art date
Application number
RU2013119044/15A
Other languages
Russian (ru)
Inventor
Василий Васильевич Панкратов
Original Assignee
Василий Васильевич Панкратов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Василий Васильевич Панкратов filed Critical Василий Васильевич Панкратов
Priority to RU2013119044/15A priority Critical patent/RU2013119044A/en
Priority to PCT/RU2014/000055 priority patent/WO2014175773A1/en
Publication of RU2013119044A publication Critical patent/RU2013119044A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Addiction (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Средство для нормализации сна, биологических ритмов человека и/или облегчения состояний, связанных с употреблением алкоголя и/или наркотических веществ, включающее мелатонин, глицин, гамма-аминомасляную кислоту, триптофан или их производные и, необязательно, дополнительные компоненты.2. Средство по п.1 при следующем соотношении компонентов, мас.%:3. Средство по п.2 при следующем соотношении компонентов, мас.%:4. Средство по п.1, отличающееся тем, что дополнительными компонентами являются витамин В6 и/или магний.5. Средство по п.1, отличающееся тем, что дополнительными компонентами являются экстракты пиона, боярышника и/или валерианы.6. Средство по п.1, отличающееся тем, что производным гамма-аминомасляной кислоты является никотиноил-гамма-аминомасляная кислота.7. Средство по п.1, отличающееся тем, что триптофан находится в L-конфигурации (L-триптофан).8. Средство по п.1 для облегчения засыпания.9. Средство по п.1 для перорального применения.10. Средство по п.1, где компоненты растворены и/или диспергированы в жидком, полутвердом или твердом носителе.11. Средство по п.1, отличающееся тем, что обеспечивается контролируемое высвобождение по крайней мере одного активного компонента.12. Средство по п.1 для купирования абстиненции при хронической алкогольной интоксикации.13. Средство по п.1 для лечения алкогольной и наркотической зависимости.14. Средство по п.1 в виде фармацевтического препарата.15. Средство по п.1 в виде биологически активной добавки.16. Средство по п.1 для приготовления функциональных продуктов питания или напитков.1. Means for normalizing sleep, human biological rhythms and / or alleviating conditions associated with the use of alcohol and / or drugs, including melatonin, glycine, gamma-aminobutyric acid, tryptophan or their derivatives and, optionally, additional components. The tool according to claim 1 in the following ratio of components, wt.%: 3. The tool according to claim 2 in the following ratio of components, wt.%: 4. The tool according to claim 1, characterized in that the additional components are vitamin B6 and / or magnesium. The tool according to claim 1, characterized in that the additional components are extracts of peony, hawthorn and / or valerian. The tool according to claim 1, characterized in that the derivative of gamma-aminobutyric acid is nicotinoyl-gamma-aminobutyric acid. The tool according to claim 1, characterized in that the tryptophan is in the L-configuration (L-tryptophan). The tool according to claim 1 to facilitate falling asleep. The tool according to claim 1 for oral administration. The tool according to claim 1, where the components are dissolved and / or dispersed in a liquid, semi-solid or solid carrier. The tool according to claim 1, characterized in that a controlled release of at least one active component is provided. The tool according to claim 1 for the relief of withdrawal symptoms in chronic alcohol intoxication. The tool according to claim 1 for the treatment of alcohol and drug addiction. The tool according to claim 1 in the form of a pharmaceutical preparation. The tool according to claim 1 in the form of a biologically active additive. The tool according to claim 1 for the preparation of functional foods or drinks.

Claims (16)

1. Средство для нормализации сна, биологических ритмов человека и/или облегчения состояний, связанных с употреблением алкоголя и/или наркотических веществ, включающее мелатонин, глицин, гамма-аминомасляную кислоту, триптофан или их производные и, необязательно, дополнительные компоненты.1. Means for normalizing sleep, human biological rhythms and / or alleviating conditions associated with the use of alcohol and / or narcotic substances, including melatonin, glycine, gamma-aminobutyric acid, tryptophan or their derivatives and, optionally, additional components. 2. Средство по п.1 при следующем соотношении компонентов, мас.%:2. The tool according to claim 1 in the following ratio of components, wt.%: мелатонин или его производноеmelatonin or a derivative thereof 0,1-20.1-2 глицин или его производноеglycine or its derivative 4-704-70 гамма-аминомасляная кислота или ее производноеgamma-aminobutyric acid or its derivative 1-801-80 триптофан или его производноеtryptophan or its derivative 1-601-60 дополнительные компонентыadditional components 0-200-20
3. Средство по п.2 при следующем соотношении компонентов, мас.%:3. The tool according to claim 2 in the following ratio of components, wt.%: мелатонин или его производноеmelatonin or a derivative thereof 0,1-10.1-1 глицин или его производноеglycine or its derivative 5-305-30 гамма-аминомасляная кислотаgamma-aminobutyric acid 30-8030-80 5-гидрокситриптофан5-hydroxytryptophan 1-101-10 дополнительные компонентыadditional components 00
4. Средство по п.1, отличающееся тем, что дополнительными компонентами являются витамин В6 и/или магний.4. The tool according to claim 1, characterized in that the additional components are vitamin B6 and / or magnesium. 5. Средство по п.1, отличающееся тем, что дополнительными компонентами являются экстракты пиона, боярышника и/или валерианы.5. The tool according to claim 1, characterized in that the additional components are extracts of peony, hawthorn and / or valerian. 6. Средство по п.1, отличающееся тем, что производным гамма-аминомасляной кислоты является никотиноил-гамма-аминомасляная кислота.6. The tool according to claim 1, characterized in that the derivative of gamma-aminobutyric acid is nicotinoyl-gamma-aminobutyric acid. 7. Средство по п.1, отличающееся тем, что триптофан находится в L-конфигурации (L-триптофан).7. The tool according to claim 1, characterized in that the tryptophan is in the L-configuration (L-tryptophan). 8. Средство по п.1 для облегчения засыпания.8. The tool according to claim 1 to facilitate falling asleep. 9. Средство по п.1 для перорального применения.9. The tool according to claim 1 for oral administration. 10. Средство по п.1, где компоненты растворены и/или диспергированы в жидком, полутвердом или твердом носителе.10. The tool according to claim 1, where the components are dissolved and / or dispersed in a liquid, semi-solid or solid carrier. 11. Средство по п.1, отличающееся тем, что обеспечивается контролируемое высвобождение по крайней мере одного активного компонента.11. The tool according to claim 1, characterized in that it provides a controlled release of at least one active component. 12. Средство по п.1 для купирования абстиненции при хронической алкогольной интоксикации.12. The tool according to claim 1 for the relief of withdrawal symptoms in chronic alcohol intoxication. 13. Средство по п.1 для лечения алкогольной и наркотической зависимости.13. The tool according to claim 1 for the treatment of alcohol and drug addiction. 14. Средство по п.1 в виде фармацевтического препарата.14. The tool according to claim 1 in the form of a pharmaceutical preparation. 15. Средство по п.1 в виде биологически активной добавки.15. The tool according to claim 1 in the form of a biologically active additive. 16. Средство по п.1 для приготовления функциональных продуктов питания или напитков. 16. The tool according to claim 1 for the preparation of functional foods or drinks.
RU2013119044/15A 2013-04-25 2013-04-25 MEANS FOR NORMALIZATION OF SLEEP AND BIOLOGICAL RHYTHMS RU2013119044A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2013119044/15A RU2013119044A (en) 2013-04-25 2013-04-25 MEANS FOR NORMALIZATION OF SLEEP AND BIOLOGICAL RHYTHMS
PCT/RU2014/000055 WO2014175773A1 (en) 2013-04-25 2014-01-24 A formula for restoring normal sleep and biological rhythms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013119044/15A RU2013119044A (en) 2013-04-25 2013-04-25 MEANS FOR NORMALIZATION OF SLEEP AND BIOLOGICAL RHYTHMS

Publications (1)

Publication Number Publication Date
RU2013119044A true RU2013119044A (en) 2014-10-27

Family

ID=51792193

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013119044/15A RU2013119044A (en) 2013-04-25 2013-04-25 MEANS FOR NORMALIZATION OF SLEEP AND BIOLOGICAL RHYTHMS

Country Status (2)

Country Link
RU (1) RU2013119044A (en)
WO (1) WO2014175773A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2682888C2 (en) * 2016-08-01 2019-03-22 Валентина Васильевна Марченкова Complex of biologically active substances for express relaxation
US20230000826A1 (en) * 2017-06-27 2023-01-05 Nightwise, Llc Time release sleep aid system
RU2829501C2 (en) * 2022-11-22 2024-10-30 Общество с ограниченной ответственностью "Симплфарм" Biologically active additive "fna 652"

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197016A1 (en) * 2016-05-10 2017-11-16 The Lester Smith Medical Research Institute, LLC Melatonin-based nasal compositions and uses thereof
RU2636471C1 (en) * 2016-07-20 2017-11-23 Александр Иванович Шубин Biologically active additive with sedative-antidepressive effect
EA035166B1 (en) * 2018-04-13 2020-05-08 Закрытое акционерное общество "Эвалар" Pharmaceutical composition having anxiolytic and hypnotic action
CN112022847B (en) * 2020-09-04 2021-09-07 华熙生物科技股份有限公司 Composition capable of improving immunity and improving sleep and preparation method and application thereof
RU2748035C1 (en) * 2020-10-08 2021-05-19 Общество С Ограниченной Ответственностью "Научно-Производственное Объединение "Фарматрон" Combined drug for pharmacorrection of cognitive dysfunctions after ketamine anesthesia
EP4431091A1 (en) * 2023-03-17 2024-09-18 Elaborados Dietéticos S.A.U. Composition with glycine for use treating insomnia disorder
CN116549462A (en) * 2023-05-06 2023-08-08 湖南微木生物科技有限公司 Composition for improving sleep quality and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419345A (en) * 1981-07-20 1983-12-06 Kinetic Systems, Inc. Sleep-inducing pharmaceutical composition and method
WO2001097818A1 (en) * 2000-06-20 2001-12-27 Isaak Grigorevitch Gitlin Fortifying vitamin compositions
US8852656B2 (en) * 2004-04-06 2014-10-07 Taiyokagaku Co., Ltd. Sleep improvement composition
JP2008150352A (en) * 2006-12-15 2008-07-03 Mg Seiyaku Kk Sleep-improving agent composition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2682888C2 (en) * 2016-08-01 2019-03-22 Валентина Васильевна Марченкова Complex of biologically active substances for express relaxation
US20230000826A1 (en) * 2017-06-27 2023-01-05 Nightwise, Llc Time release sleep aid system
US11890271B2 (en) * 2017-06-27 2024-02-06 Nightwise, Llc Time release sleep aid system
US12419860B2 (en) 2017-06-27 2025-09-23 Nightwise, Llc Time release sleep aid system
RU2829501C2 (en) * 2022-11-22 2024-10-30 Общество с ограниченной ответственностью "Симплфарм" Biologically active additive "fna 652"

Also Published As

Publication number Publication date
WO2014175773A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
RU2013119044A (en) MEANS FOR NORMALIZATION OF SLEEP AND BIOLOGICAL RHYTHMS
Brown et al. Low-dose naltrexone for disease prevention and quality of life
CY1125292T1 (en) 6,7,8,9-TETPAYDP-3H-PYPAZOLO[4,3-F ISOQUINOLINE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
Djamshidian et al. Apomorphine and levodopa in Parkinson's disease: two revolutionary drugs from the 1950's
CA2968703A1 (en) Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
RU2015143836A (en) Leucine and Niacin to Reduce Lipid Levels
AR078812A1 (en) PREPARATION THAT INCLUDES AMINO ACIDS AND PLANTS AND ITS ACTIVITY IN THE DETOXIFICATION OF ALCOHOL
US20180147142A1 (en) Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
MX2013012206A (en) Method of producing substances with supersaturated gas, transdermal delivery thereof, and uses thereof.
EA201690974A1 (en) HYDROMORPHONE AND NALOXONE FOR THE TREATMENT OF PAIN AND OPIOID-INITIATED INTESTINAL DYSFUNCTION SYNDROME
PH12015502517A1 (en) Compositions and methods for nutrient delivery
EA201491831A1 (en) CONTAINING PRASONAUTIC STABLE PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELIEF FOR PERIAL INTRODUCTION
MX2013012204A (en) Method of producing substances with supersaturated gas,transdermal delivery device thereof, and uses thereof.
RU2012136775A (en) METHOD AND MEANS FOR INCREASING ADAPTIVE POSSIBILITIES OF AN ATHLETES ORGANISM DURING THE TRAINING PROCESS
RU2011127055A (en) MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT
RU2015156397A (en) COMPLEXES BASED ON VITAMIN D AND THEIR APPLICATION IN THERAPY
PH12014502494A1 (en) Parenteral esmolol formulation
EA201500367A1 (en) PHARMACEUTICAL COMPOSITION OF 1-ADAMANTYLETHYLOXY-3-MORFOLINO-2-PROPANOLAL OR ITS PHARMACEUTICALLY-ACCEPTABLE SALTS FOR THE TREATMENT OF CEREBROVASCULAR PATHOLOGY AND NEURODYGENIRHYIALLYAHI IMPERSING INHCHES OF ANIMAL IMPERSING ANIMAL IMPERSHIPS AND NIRODYGENAIRS OF INTRACTING CEREBROVASCULAR PATHOLOGY AND NEURODYGENIRTHILE IMPERSING INCHILEAUTING IMPING ITURING INHRECTING PATHOLOGY
CY1120282T1 (en) PHARMACEUTICAL COMPOSITION OF SILDENAFIL CITRUS IN THE FORM OF AN ORAL DRIVE FOR USE
Litvinenko et al. Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia
RU2013127881A (en) APPLICATION OF THE PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY AND SUBSTITUTED DINITROBENZOFUROXAN FOR THE TREATMENT OF Pyroplasmosis in Dogs and the Method of Treatment
RU2008140019A (en) METHOD FOR TREATMENT AND PREVENTION OF ENDOMETRITIS IN COWS
RU2011103923A (en) COMPOSITION FOR VETERINARY MEDICINE CONTAINING human recombinant interferon alfa-2B, tocopherol acetate and ascorbic acid, a drug for veterinary MULTIFERON® AT ITS BASE AND APPLICATION OF DRUG MULTIFERON® as an antiviral and immunomodulating agents in the vaccination schedule of young farm animals
MX2016017001A (en) Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine.
Ebrahimi et al. Evaluation of analgesic effect of piroxicam liquisolid system in rat and comparison with conventional formulation